Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 297

1.

Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.

Kim YA, Trinh S, Thura S, Kyi KP, Lee T, Sze S, Richards A, Aronsohn A, Wong GLH, Tanaka Y, Dusheiko G, Nguyen MH.

PLoS One. 2017 Aug 10;12(8):e0181603. doi: 10.1371/journal.pone.0181603. eCollection 2017.

2.

Hepatitis B cure: From discovery to regulatory approval.

Lok AS, Zoulim F, Dusheiko G, Ghany MG.

J Hepatol. 2017 Oct;67(4):847-861. doi: 10.1016/j.jhep.2017.05.008. Epub 2017 Aug 1. Review.

PMID:
28778687
3.

Hepatitis B cure: From discovery to regulatory approval.

Lok AS, Zoulim F, Dusheiko G, Ghany MG.

Hepatology. 2017 Oct;66(4):1296-1313. doi: 10.1002/hep.29323. Epub 2017 Aug 1.

PMID:
28762522
4.

Hepatitis C in the EU: setting the terms for elimination.

Dusheiko G.

Lancet Gastroenterol Hepatol. 2017 May;2(5):314-315. doi: 10.1016/S2468-1253(17)30073-0. Epub 2017 Mar 15. No abstract available.

PMID:
28397690
5.

The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.

Dusheiko G.

Liver Int. 2017 Jan;37 Suppl 1:7-12. doi: 10.1111/liv.13292. Review.

PMID:
28052638
6.

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.

Kim YA, Estevez J, Le A, Israelski D, Baatarkhuu O, Sarantuya T, Narantsetseg S, Nymadawa P, H Le R, Yuen MF, Dusheiko G, Rizzetto M, Nguyen MH.

BMJ Open Gastroenterol. 2016 Nov 10;3(1):e000119. eCollection 2016.

7.

Bringing to an end mother-to-child transmission of hepatitis B: A role for quantitative hepatitis B surface antigen?

Dusheiko G, Easterbrook P.

Hepatology. 2016 Nov;64(5):1408-1410. doi: 10.1002/hep.28732. Epub 2016 Aug 27. No abstract available.

PMID:
27452950
8.

Conceptual framework for outcomes research studies of hepatitis C: an analytical review.

Sbarigia U, Denee TR, Turner NG, Wan GJ, Morrison A, Kaufman AS, Rice G, Dusheiko GM.

Infect Drug Resist. 2016 May 27;9:101-17. doi: 10.2147/IDR.S99329. eCollection 2016. Review.

9.

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy.

Dusheiko G, Wang B, Carey I.

Hepatol Int. 2016 Sep;10(5):727-9. doi: 10.1007/s12072-016-9738-1. Epub 2016 May 31. No abstract available.

PMID:
27246696
10.

Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.

Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, Amorós À, Mookerjee RP, Xia Q, Xue F, Ma X, Hua J, Sheng L, Qiu DK, Xie Q, Foster GR, Dusheiko G, Moreau R, Gines P, Arroyo V, Jalan R.

Sci Rep. 2016 May 5;6:25487. doi: 10.1038/srep25487.

11.

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.

Yuen MF, Ahn SH, Chen DS, Chen PJ, Dusheiko GM, Hou JL, Maddrey WC, Mizokami M, Seto WK, Zoulim F, Lai CL.

J Clin Gastroenterol. 2016 Apr;50(4):286-94. doi: 10.1097/MCG.0000000000000478. Review.

PMID:
26840752
13.

Pregnancy and liver disease.

Westbrook RH, Dusheiko G, Williamson C.

J Hepatol. 2016 Apr;64(4):933-45. doi: 10.1016/j.jhep.2015.11.030. Epub 2015 Nov 30. Review.

PMID:
26658682
14.

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.

Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J.

Gut. 2016 Feb;65(2):340-50. doi: 10.1136/gutjnl-2015-310317. Epub 2015 Oct 15. Review.

PMID:
26475631
15.

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.

Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.

PMID:
26449729
16.

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H.

Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007. Epub 2015 Jul 27.

17.

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".

Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C; EASL Recommendations on Treatment of Hepatitis C 2015 panel.

J Hepatol. 2015 Dec;63(6):1535-6. doi: 10.1016/j.jhep.2015.09.004. Epub 2015 Sep 12. No abstract available.

PMID:
26375242
18.

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.

Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, Dusheiko G, Rosenberg WM, Haque T.

Springerplus. 2015 Jul 16;4:357. doi: 10.1186/s40064-015-1137-x. eCollection 2015.

19.

Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.

Kalafateli M, Dusheiko G, Manousou P.

J Gastrointestin Liver Dis. 2015 Jun;24(2):257-8. No abstract available.

20.

Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.

Stockdale AJ, Phillips RO, Beloukas A, Appiah LT, Chadwick D, Bhagani S, Bonnett L, Sarfo FS, Dusheiko G, Geretti AM; Hepatitis B Infection in Kumasi (HEPIK) Study Group.

Clin Infect Dis. 2015 Sep 15;61(6):883-91. doi: 10.1093/cid/civ421. Epub 2015 May 28.

PMID:
26021992

Supplemental Content

Loading ...
Support Center